((自动化翻译由路透提供，请见免责声明 ))
10月30日 - ** 安进 在周三收盘后公布第三季度财报前股价下跌0.1%，至315.56美元。
** 根据伦敦证券交易所集团的数据，这家生物技术公司预计第三季度每股收益为5.11美元，营收为85.2亿美元，而去年同期每股收益为4.96美元，营收为69亿美元。
** 在过去 8 个季度中，AMGN 有 6 个季度的每股收益达到或超过预期，最近一次未达预期是在 2024 年第二季度。
** 在 32 位覆盖安进公司的分析师中，17 位给予 "强烈买入 "或 "买入 "评级，13 位给予 "持有 "评级，2 位给予 "卖出 "或 "强烈卖出 "评级。 ** AMGN目前正在努力争取减肥药MariTide的批准；礼来 周三股价暴跌~8%，因为其减肥药的销售额未达到预期 (link)。
** AMGN股价今年以来上涨了9.5%，而道琼斯工业指数 上涨了12%。 ** 期权
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.